BICO grows IP portfolio with patents in the United States and Sweden

The innovations will allow for better cell viability and lower maintenance bioprinting and thus help accelerate exploring drug discovery and scientific research

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

BICO, an expert bio convergence company, has been granted two patents relating to the regulation and control of temperatures in 3D Bioprinters. The first patent, US 11,046,001, was granted in the United States and relates to the temperature regulation of bioinks which allows for better cell viability during 3D bioprinting. The second patent, SE 543880, was granted in Sweden and relates to controlling the temperature of the dispensing nozzle during the 3D bioprinting leading to increased printing consistency, less downtime due to clogging, and less material waste.

“Our mission at BICO is to create the future of medicine and improve health globally through the convergence of key biotechnologies,” explained Erik Gatenholm, CEO and Co-Founder of BICO. “This innovation will help our incredible customers drive advancements across drug discovery, tissue engineering, and disease modeling.”

BICO believes 3D bioprinting will help accelerate drug development and eventually alleviate the strain on organ transplants and this patent is an important milestone in that mission. It is vital during the printing process to maintain a constant temperature to keep cells alive at 37 degrees Celsius. Temperature control is also very helpful while using bioinks like Gelma and Collagen to avoid clogging the needles and nozzles. The two patents strengthen the company’s protection for intellectual properties and complement a full portfolio of solutions being developed by BICO and its subsidiary CELLINK.

BICO has been granted two patents relating to the regulation and control of temperatures in 3D Bioprinters

“At BICO we work tirelessly to consistently improve and innovate our bioprinting offerings,” said Dr. Héctor Martínez, co-founder and Chief Technology Officer of BICO. “Our customers around the world are continuously pushing the limits of science using our technology and I’m excited to see how they use these innovations to help make the world a healthier place.”

3D bioprinting is an essential tool for the fabrication of soft materials, tissue models, and 3D cell culture environments. As the global 3D bioprinting leader, BICO and CELLINK have developed breakthrough technologies for biofabrication, including extrusion-based bioprinters, light-based bioprinters, live-cell imaging devices, inks, and accessories. The company’s products are in more than 2,000 of the world’s most innovative labs including Stanford, Harvard, Merck, Novartis, AstraZeneca, Johnson & Johnson, and others.

Research 2022
Polymer AM Market Opportunities and Trends

741 unique polymer AM companies individually surveyed and studied. Core polymer AM market generated $4.6 billion...

Andrea Gambini

Andrea has always loved reading and writing. He started working in an editorial office as a sports journalist in 2008, then the passion for journalism and for the world of communication in general, allowed him to greatly expand his interests, leading to several years of collaborations with several popular online newspapers. Andrea then approached 3D printing, impressed by the great potential of this new technology, which day after the day pushed him to learn more and more about what he considers a real revolution that will soon be felt in many fields of our daily life.

Related Articles

Back to top button

We use cookies to give you the best online experience and for ads personalisation. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services



Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*